Titan Pharmaceuticals (NASDAQ:TTNP) and Silexion Therapeutics (NASDAQ:SLXN) Head to Head Review

Silexion Therapeutics (NASDAQ:SLXN) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Volatility & Risk

Silexion Therapeutics has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.

Insider & Institutional Ownership

10.9% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are held by institutional investors. 33.0% of Silexion Therapeutics shares are held by company insiders. Comparatively, 24.9% of Titan Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Silexion Therapeutics and Titan Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	$260,000.00	N/A	N/A
Titan Pharmaceuticals	$180,000.00	19.12	-$5.57 million	($5.21)	-0.72

Silexion Therapeutics has higher earnings, but lower revenue than Titan Pharmaceuticals.

Profitability

This table compares Silexion Therapeutics and Titan Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	N/A	-249.43%
Titan Pharmaceuticals	N/A	-118.01%	-103.79%

Analyst Recommendations

This is a breakdown of current recommendations for Silexion Therapeutics and Titan Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	0	0	1	0	3.00
Titan Pharmaceuticals	0	0	0	0	0.00

Silexion Therapeutics currently has a consensus target price of $5.00, indicating a potential upside of 479.58%. Given Silexion Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Silexion Therapeutics is more favorable than Titan Pharmaceuticals.

Summary

Silexion Therapeutics beats Titan Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.